| Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial P Piola, C Fogg, F Bajunirwe, S Biraro, F Grandesso, E Ruzagira, ... The Lancet 365 (9469), 1467-1473, 2005 | 255 | 2005 |
| Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis S Verguet, ZD Olson, JB Babigumira, D Desalegn, KA Johansson, ... The Lancet Global Health 3 (5), e288-e296, 2015 | 131 | 2015 |
| Global eradication of measles: an epidemiologic and economic evaluation A Levin, C Burgess, LP Garrison, C Bauch, J Babigumira, E Simons, ... The Journal of infectious diseases 204 (suppl_1), S98-S106, 2011 | 106 | 2011 |
| Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems L Roth, D Bempong, JB Babigumira, S Banoo, E Cooke, D Jeffreys, ... Globalization and Health 14, 1-12, 2018 | 82 | 2018 |
| Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda F Checchi, P Piola, C Fogg, F Bajunirwe, S Biraro, F Grandesso, ... Malaria journal 5, 1-8, 2006 | 82 | 2006 |
| People living with HIV travel farther to access healthcare: a population‐based geographic analysis from rural Uganda AN Akullian, A Mukose, GA Levine, JB Babigumira African Journal of Reproduction and Gynaecological Endoscopy 19 (1), 2016 | 78 | 2016 |
| Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda JB Babigumira, B Castelnuovo, A Stergachis, A Kiragga, P Shaefer, ... Plos one 6 (3), e18193, 2011 | 65 | 2011 |
| Pharmaceutical availability across levels of care: evidence from facility surveys in Ghana, Kenya, and Uganda SH Masters, R Burstein, B DeCenso, K Moore, A Haakenstad, G Ikilezi, ... PloS one 9 (12), e114762, 2014 | 59 | 2014 |
| Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda JB Babigumira, B Castelnuovo, M Lamorde, A Kambugu, A Stergachis, ... BMC health services research 9, 1-6, 2009 | 58 | 2009 |
| Telehealth for acute and chronic care consultations AM Totten, RN Hansen, J Wagner, L Stillman, I Ivlev, C Davis-O’Reilly, ... | 57 | 2019 |
| Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda JB Babigumira, AK Sethi, KA Smyth, ME Singer Pharmacoeconomics 27, 963-973, 2009 | 55 | 2009 |
| Health technology assessment in low-and middle-income countries: a landscape assessment JB Babigumira, AM Jenny, R Bartlein, A Stergachis, LP Garrison Journal of Pharmaceutical Health Services Research 7 (1), 37-42, 2016 | 54 | 2016 |
| Estimating the costs of induced abortion in Uganda: a model-based analysis JB Babigumira, A Stergachis, DL Veenstra, JS Gardner, J Ngonzi, ... BMC public health 11, 1-9, 2011 | 53 | 2011 |
| Health economics of rubella: a systematic review to assess the value of rubella vaccination JB Babigumira, I Morgan, A Levin BMC Public Health 13, 1-12, 2013 | 52 | 2013 |
| Use of the Fogg behavior model to assess the impact of a social marketing campaign on condom use in Pakistan S Agha, D Tollefson, S Paul, D Green, JB Babigumira Journal of health communication 24 (3), 284-292, 2019 | 47 | 2019 |
| Potential cost-effectiveness of universal access to modern contraceptives in Uganda JB Babigumira, A Stergachis, DL Veenstra, JS Gardner, J Ngonzi, ... PloS one 7 (2), e30735, 2012 | 43 | 2012 |
| Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of HER2-positive breast cancer in … LP Garrison Jr, J Babigumira, C Tournier, HP Goertz, SJ Lubinga, ... Value in health 22 (4), 408-415, 2019 | 38 | 2019 |
| Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status LP Garrison Jr, D Lalla, M Brammer, JB Babigumira, B Wang, EA Perez Cancer 119 (17), 3113-3122, 2013 | 37 | 2013 |
| A cost-effectiveness tool to guide the prioritization of interventions for rheumatic fever and rheumatic heart disease control in African nations D Watkins, SJ Lubinga, B Mayosi, JB Babigumira PLOS Neglected Tropical Diseases 10 (8), e0004860, 2016 | 32 | 2016 |
| The lifetime economic burden of inaccurate HER2 testing: estimating the costs of false-positive and false-negative HER2 test results in US patients with early-stage breast cancer LP Garrison Jr, JB Babigumira, A Masaquel, BCM Wang, D Lalla, ... Value in health 18 (4), 541-546, 2015 | 32 | 2015 |
